PharmaTher Faces FDA Setback for Ketamine Drug
Company Announcements

PharmaTher Faces FDA Setback for Ketamine Drug

Story Highlights
  • PharmaTher received an FDA letter citing minor deficiencies in its ketamine drug application.
  • The company is committed to resolving issues to address the U.S. ketamine shortage.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

PharmaTher Holdings Ltd (TSE:PHRM) has released an update.

PharmaTher Holdings Ltd. announced that the FDA has issued a complete response letter for its ketamine drug application, citing minor deficiencies that need to be addressed. The company is working with its partners to resolve these issues and aims to tackle the ketamine shortage in the U.S. by adhering to FDA guidelines. Despite the setback, PharmaTher remains committed to providing FDA-approved ketamine solutions, especially as compounded versions flood the market without approval.

For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyPharmaTher receives CRL from FDA for ketamine ANDA
TipRanks Canadian Auto-Generated NewsdeskPharmaTher Closes in on FDA Ketamine Approval Date
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App